Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· July 29, 2026
Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
View original at finance.yahoo.comSales of Leqembi® totaled 29.3 billion yen in the second quarter 2026 STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter…
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The Leqembi royalty to BioArctic was SEK 179 million in Q2 2026, an increase of approximately 10 percent compared to Q2 2025.
60% confidenceExcluding a one-time Q2 2025 stockpiling effect in China of approximately JPY 5.3 billion, royalty revenues in Q2 2026 grew approximately 43 percent year-over-year.
60% confidenceTotal sales of Leqembi were JPY 29.3 billion in the second quarter of 2026.
60% confidence
Cité dans ces articles de Via News
- A Phase 3 kidney result holds up for two years while the AI-tech selloff tests biotech's funding →
- Biotech Grows Up: A Phase 3 Win, a Profitable Incyte and Royalty Income, While the Early Pipeline and AI Drugs Still Have to Prove Themselves →
- Biotech's Science Is Advancing While Its Funding Backdrop Tightens: What the Verified Numbers Show →
